Biosimilars

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Pharmacists will need to evaluate several new factors when selecting and dispensing products.

With biosimilars set to enter the US health care market, pharmacists will soon have new factors to consider when selecting and dispensing products.

Top stories of the week on Specialty Pharmacy Times from July 13 to July 17.

Pfizer executive discusses the present and future of biosimilars.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how specialty pharmacies can best manage the rising cost of specialty drugs to improve outcomes for patients.

There are currently more than 600 trials of biosimilars ongoing.

Fred Eckel, RPh, MS, Editor-in-Chief of Pharmacy Times, reflects on how pharmacists will be affected by FDA approvals of biosimilars.

The first biosimilar product in the United States has been approved, and the time is now for specialty pharmacists to become familiar with the use and regulation of these drugs.

Biosimilars are finally a reality in the US drug market, but a report warns regulatory decisions may limit future savings from the drugs.

FDA approves Zarxio for the same indications as Neupogen.

New recommendations involve drugs containing several adapalene formulations.

Raulo Frear, PharmD, general manager of OmedaRx, discusses the ramifications of biosimilars hitting the US market.

Filgrastim is indicated to decrease the incidence of infection in patients with non-myeloid malignancies who also are receiving myelosuppressive anti-cancer drugs.

The Academy of Managed Care Pharmacy today supported the U.S. Food and Drug Administration's use of "an expedited approval process" for biosimilars to encourage the development of both new and more affordable treatments for such serious conditions as cancer, multiple sclerosis and rheumatoid arthritis.

Landmark generic labeling rulings may foreshadow the issues that lie ahead when biosimilars enter the US market.

Significant challenges remain due to lack of FDA action on existing biosimilar approval guidelines.

Pharmacists will play key role in bringing biosimilar medications to US markets, both before the therapies receive FDA approval and after they become available.

GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.

RAND Corporation projects biosimilars to cause an approximately 4% reduction in total US biologic spending from 2014 to 2024.

Biosimilars are an estimated 30% cheaper than branded biologics

Biologics License Application filed for filgrastim by Sandoz.

Survey finds an overwhelming number of seniors are unaware of what biosimilars are.